# Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

> **NCT00343759** · PHASE2 · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT00343759
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-06
- **Primary completion:** 2009-05
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343759, "Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00343759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*